Everpure Stock Climbs 34% On A 9-Day Winning Streak

SPYYTD+14.9%QQQYTD+24.0%
Analyze P →

Everpure (P) stock has risen for 9 consecutive trading days, gaining 34.2% over that stretch. That added about $12.5 billion to the company’s market value, which now stands at about $49.0 billion. The stock closed at $147.20 on Tuesday, October 6.

Image from Pixabay

 
The Streak Next To The S&P 500

Returns for P and the S&P 500 over the streak and the periods around it, all ending Tuesday, October 6 and including dividends:
 

Return Period P S&P 500
1 Day 2.3% 0.6%
9 Days (Current Streak) 34.2% 1.5%
1 Month (21 Trading Days) 47.9% 1.4%
3 Months (63 Trading Days) 89.4% 4.8%

A Stock-Specific Run, Or A Market Move?

Over the same 9 trading days, the S&P 500 returned +1.5% including dividends, so the run is mostly Everpure’s own story rather than the market’s. No other S&P 500 stock is currently on a winning streak of 9 days or longer. Over the past three months the stock is up 89.4%, a window that includes the streak; over the other 54 sessions of that window it was up 41.1%.

Do The Fundamentals Support The Run?

On the fundamentals, revenue grew 27.2% over the last twelve months, against a median of 17.9% for S&P 500 Information Technology stocks; its operating margin is 5.3%, versus a median of 21.7%; and the stock trades at 193.5 times trailing earnings against a median of 36.6. The numbers make the run harder to justify: margins below the median and a multiple well above the median. At this price, the stock is asking a lot of the business.

A climb like this is worth respecting, and worth testing. Our Guidance Momentum screen tracks the stocks whose companies just raised their own forward numbers.

One Hot Stock Is A Story. Thirty Sound Ones Are A Strategy

A streak like this earns a place on your watchlist, and it also earns a question: how much of your outcome do you want depending on one company keeping this up?

The Trefis High Quality (HQ) Portfolio answers it with breadth: roughly 30 businesses picked for consistent cash generation, strong margins, and balance-sheet strength, sized and rebalanced by rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Follow the story; invest in the strategy.